| Cancer |
| ● A Phase 1 Study of Dexanabinol in Patients With Advanced Solid Tumours |
Recruiting |
 e-Therapeutics PLC |
| ● Sativex for Treatment of Chemotherapy Induced Neuropathic Pain |
Ongoing |
 CDHA |
| ● Orexigenic Therapy With Delta-9-Tetrahydrocannabinol in Advanced Cancer Patients With Chemosensory Abnormalities - a Pilot Study |
Completed |
Alberta |
| ● Opioid and Cannabinoid Pharmacokinetic Interactions |
Completed |
 NIDA |
| ● A Phase IV Trial of Cesamet™ Given With Standard Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting |
Terminated |
Veeda |
| Diabetes/Diet |
| ● Effect of Rimonabant on Weight Gain and Body Composition in Adults With Prader Willi Syndrome |
Recruiting |
Cornell |
| ● GWMD1092 - GW42003 : GW42004 Together Plus Alone in Type II Diabetes |
Completed |
GWPharm |
| ● Appetite Increase in Schizophrenia Patients Treated With Atypical Antipsychotics |
Unknown |
UdeM |
| ● Diagnosis and Therapy of Vulnerable Atherosclerotic Plaque |
Completed |
 AUTH |
| ● The Effects of Rimonabant, on Weight and Metabolic Risk Factors |
Terminated |
Maryland |
| ● Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients on Diet and Exercise |
Terminated |
 Sanofi |
| ● Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients With Oral Anti-Diabetic Drug |
Terminated |
Sanofi |
| ● Japanese Study of Rimonabant in Obese Patients With Dyslipidemia (VENUS) |
Terminated |
Sanofi |
| Fibromyalgia |
| ● A Trial Assessing the Effect of Nabilone on Pain and Quality of Life in Patients With Fibromyalgia |
Completed |
Manitoba |
| ● Nabilone Versus Amitriptyline in Improving Quality of Sleep in Patients With Fibromyalgia |
Completed |
McGill |
| ● Supporting Effect of Dronabinol on Behavioral Therapy in Fibromyalgia and Chronic Back Pain |
Completed |
 Heidelberg |
| HIV/AIDS |
| ● Combination of an Investigational Cannabinoid and Methadone for HIV-Associated Neuropathy |
Terminated |
UW |
| Inflammatory Bowel Disease |
| ● Cannabis for Inflammatory Bowel Disease |
Recruiting |
 Meir |
| ● Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor and Sensory Functions in Patients With Irritable Bowel Syndrome (IBS) |
Completed |
Mayo |
| Multiple Sclerosis |
| ● Cannabis for Spasticity in Multiple Sclerosis |
Recruiting |
UCDavis |
| ● Use of Cannabinoids in Patients With Multiple Sclerosis |
Unknown |
 Rome |
| ● Novel Immune Markers in Patients With Multiple Sclerosis (NIMMS) |
Unknown |
UW |
| ● MUltiple Sclerosis and Extract of Cannabis (MUSEC) Study |
Terminated |
IKFE |
| Pain |
| ● Delta-THC in Pain in Dementia |
Beginning |
Radboud |
| ● The Effects of Cannabinoid on Patients With Non-GERD Related Non Cardiac Chest Pain |
Recruiting |
U Iowa |
| ● Cannabinoid Modulation of Pain |
Recruiting |
Yale |
| ● Efficacy Study of Δ9-THC to Treat Chronic Abdominal Pain (Delta-pain) |
Recruiting |
Radboud |
| ● Sativex for Treatment of Chemotherapy Induced Neuropathic Pain |
Recruiting |
CDHA |
| ● In Vitro Studies on Pharmacological Regulation and Genetic Risk Factors of Peripheral Human Nociceptors |
Recruiting |
Texas |
| ● Study to Evaluate the Efficacy of Dronabinol (Marinol) as Add-On Therapy for Patients on Opioids for Chronic Pain |
Unknown |
Boston |
| ● Nabilone for the Treatment of Phantom Limb Pain |
Completed |
Manitoba |
| ● Opioid and Cannabinoid Pharmacokinetic Interactions |
Completed |
NIDA |
| ● Supporting Effect of Dronabinol on Behavioral Therapy in Fibromyalgia and Chronic Back Pain |
Completed |
Heidelberg |
| ● Efficacy Study of Nabilone in the Treatment of Diabetic Peripheral Neuropathic Pain |
Unknown |
Calgary |
| ● Use of the Cannabinoid Nabilone for the Promotion of Sleep in Chronic, Non-Malignant Pain Patients |
Unknown |
Toronto |
| ● Efficacy of Dronabinol for the Treatment of Cervical Dystonia |
Unknown |
Toronto |
| ● Characterization of the Analgesic Effects of Oral THC and Smoked Marijuana in Non-Treatment Seeking Marijuana Smokers |
Unknown |
NIDA |
| Atopic Dermatitis |
| ● A Phase Ib/IIa, Double-Blind, Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Atopic Dermatitis |
Completed |
Shionogi |
| Graft Versus Host Disease |
| ● Cannabidiol for Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation |
Recruiting |
Rabin |
| ● Safety and Efficacy of Cannabidiol for Grade I/II Acute Graft Versus Host Disease (GVHD) After Allogeneic Stem Cell Transplantation |
Recruiting |
Rabin |
| Mental Health |
| ● Cannabinoid Augmentation of Fear Response in Humans |
Recruiting |
Yale |
| Addiction |
| ● Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment (ACCENT) |
Beginning |
Medical University of South Carolina |
| ● Behavioral Effects of Tiagabine and Cannabis |
Recruiting |
U Kentucky |
| ● Imaging Cannabinoid CB1 Receptors in Alcohol Dependence |
Recruiting |
NIMH |
| ● Effects of Sativex(Registered Trademark) and Oral THC on Attention, Affect, Working Memory, Reversal Learning, Physiology and Brain Activation |
Completed |
NIDA |
| ● A Trial of N-Acetylcysteine (an Over-the-Counter Medicine) in Adolescents Who Smoke Marijuana |
Unknown |
MUSC |
| ● Cannabinoid Receptor Function & Alcoholism |
Recruiting |
Yale |
| ● Safety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal |
Recruiting |
Yale |
| ● Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia (DCCS) |
Recruiting |
Mclean Hospital |
| ● Oral Fluid, Plasma and Whole Pharmacokinetics and Stability Following Smoked Cannabis |
Recruiting |
NIDA |
| ● Exercise as a Treatment for Substance Use Disorders Protocol |
Ongoing |
U Texas SW Medical Center |
| ● Dual Diagnosis (Psychosis and Cannabismisuse): Comparison of Specialized Treatment Versus Unspecified Treatment |
Completed |
Konstanz |
| ● Effect of Lofexidine and Oral THC on Marijuana Withdrawal and Relapse |
Completed |
NYPsych |
| ● Antagonist-Elicited Cannabis Withdrawal |
Completed |
NIDA |
| ● Rimonabant to Reduce Alcohol Consumption |
Completed |
NIAAA |
| ● Efficacy and Safety of Surinabant Treatment as an Aid to Smoking Cessation (SURSMOKE) |
Completed |
 Sanofi |
| ● Abuse Potential of Sativex |
Completed |
GW Pharma |
| Anorexia Nervosa |
| ● Cannabinoid Receptor (CB1) Agonist Treatment in Severe Chronic Anorexia Nervosa |
Unknown |
 Odense |
| Anxiety Disorders |
| ● Add on Study on delta 9- THC Treatment for Posttraumatic Stress Disorders (PTSD) |
Ongoing |
Hadassah |
| ● Marinol in Trichotillomania or Obsessive Compulsive Disorder |
Completed |
UMN |
| ● Cannabinoids in Bipolar Affective Disorder |
Ongoing |
UBC |
| Schizophrenia / Psychosis |
| ● Chronic Cannabis Users: A Model for Negative Symptoms in Schizophrenia |
Recruiting |
Shalvata |
| ● Gamma-Amino Butyric Acid (GABA) Deficits and Vulnerability to Cannabinoid-Induced Psychosis |
Recruiting |
Yale |
| ● Cannabinoids, Neural Synchrony, and Information Processing |
Recruiting |
Yale |
| ● Imaging Cannabinoid CB1 Receptors in Schizophrenia |
Recruiting |
NIMH |
| ● Effects of Delta-9-THC and Iomazenil in Healthy Humans |
Recruiting |
Yale |
| ● The Effects of Cannabidiol and ∆-9-THC in Humans |
Recruiting |
Yale |
| ● Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia |
Recruiting |
Yale |
| ● A Clinical Trial on the Antipsychotic Properties of Cannabidiol |
Completed |
Cologne |
| ● Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic Psychosis |
Completed |
Cologne |
| ● Dual Diagnosis (Psychosis and Cannabismisuse): Comparison of Specialized Treatment Versus Unspecified Treatment |
Completed |
Konstanz |
| ● Niacin Flushing as Marker of Cannabis Effects on Arachidonic Acid Pathways in Schizophrenia |
Completed |
Jena |
| ● Efficacy and Safety of AVE1625 as a co-Treatment With Antipsychotic Therapy in Schizophrenia |
Terminated |
Sanofi |
| ● Appetite Increase in Schizophrenia Patients Treated With Atypical Antipsychotics |
Unknown |
UdeM |
Accessed at: http://www.clinicaltrials.gov/ct2/results?term=cannabinoids&pg=1
Radboud